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Abstract  
The aim of this paper is to identify benchmark cost-efficient General Practitioner (GP) units at 
delivering health care in the Geriatric and General Medicine (GMG) specialty and estimate 
potential cost savings. The use of a single medical specialty makes it possible to reflect more 
accurately the medical condition of the List population of the Practice so as to contextualize its 
expenditure on care for patients. We use Data Envelopment Analysis (DEA) to estimate the 
potential for cost savings at GP units and to decompose these savings into those attributable 
to the reduction of resource use, to altering the mix of resources used and to those 
attributable to securing better resource ‘prices’.  The results reveal a considerable potential for 
savings of varying composition across GP units.  
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1. Introduction 
In the UK health care is free at the point of delivery for all residents. All individuals covered 
by the National Health Service (NHS) are registered with a General Practitioner (GP) who in 
turn normally delivers his/her services within a GP unit, or Practice, comprising one or more 
GPs. The Practice is the gateway for the individual to health care under the NHS. A GP within a 
Practice is responsible for the clinical decision whether or not to refer a patient for further 
medical care, (normally at a hospital), the type of initial referral (e.g. inpatient or outpatient 
treatment) and indeed the medical specialty that would be appropriate for the referral.  The 
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(primary) medical diagnosis associated with a referral would place the patient in a ‘Healthcare 
Resource Group’ (HRG) and the care provider - generally a hospital - will be compensated then 
by the Primary Care Trust (PCT) at the tariff applicable to that HRG. It is clear therefore that 
the costs incurred by a PCT for medical care of the patients it covers depend crucially on the 
clinical pathways the GPs decide upon. This study in effect captures the economic 
consequences of varying GP choices on pathways, controlling for disease weight, under an 
implicit assumption that patient outcomes are not compromised albeit they may be reached 
by alternate pathways. 
Our analysis in this paper follows the work initiated in Thanassoulis et al. (2012) where 75 
GP units have been compared on referral and drug prescription costs. In that paper overall 
inpatient referrals, outpatient referrals and drug prescription costs were compared amongst 
GP units controlling for their list population characteristics. The focus on referrals relates to 
the fact that the way physicians approach such treatment influences several aspects of patient 
care, including its quality and cost. As mentioned in Barnett et al (2011), in a survey comparing 
referral decisions of specialist and primary care physicians, different physicians have different 
reasons for choosing their referral partners. (In their study they found, for example, that 
primary care physicians were more likely to be concerned with patient access than specialist 
doctors). 
In Thanassoulis et al. (2012) the aim was to understand how Practices compare with each 
other on costs and volumes of referrals and drug prescriptions. Although differing costs 
amongst Practices were contextualised by the characteristics of the list population served, 
those characteristics reflect only indirectly their actual health needs.  In order to try to account 
for the health needs of the people served by the Practice more directly, we need to know the 
type of diseases they had and the complexity and severity of the condition they presented at 
the point the Practice decided on a treatment pathway. However, the disease types are varied 
and for clinical and accounting purposes they are classified in this study into 11 clinical 
specialties. In addition, within each specialty patients entering the hospital are assigned a 
primary diagnostic (ICD –International Classification of Diseases) code. It is this code which is 
principally responsible for placing them within a HRG which in turn determines the financial 
remuneration or payment the care provider will get for the patient episode concerned. In the 
UK there are several hundred HRGs onto which several thousand ICDs are mapped. Base tariffs 
for patient (or more precisely ‘consultant’) episodes within each HRG are set nationally by the 
Department of Health. 
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In order to account for the varied health needs of the population, we undertake in this 
paper a comparative analysis of costs of Practices (we are modeling particularly inpatient and 
outpatient referrals costs and drug prescription costs) for one particular medical specialty. The 
specialty analysed is the General Medicine and Geriatrics (GMG) combined specialty. This is 
amongst the specialties representing the highest percentage of the total costs of a Practice. (It 
represents on average about 22% of total inpatient costs of a Practice and 12% of its total 
outpatient referral costs.) 
Controlling for the GMG related disease weight of each Practice we identify three potential 
components of cost savings: savings through reducing the volumes of referrals and drugs, 
savings through switching between types of referrals and/or drugs, and savings through 
securing a better unit cost profile for referrals and drugs. The latter component may appear 
counter-intuitive given that most payments for referrals and drugs are standardized and based 
on ‘Payment by Results’ (PbR) national tariffs. Nevertheless Practices can to an extent affect 
unit costs by better targeting providers at referral stage. For example, indicating accurately the 
disease code applicable to a referral will avoid a referred patient undergoing a second 
diagnosis in hospital to correct a poorly specified initial one, for which nevertheless a fee 
would still be paid by the PCT.  Similarly, a Practice may press for prompt hospital discharge to 
reliable family care where applicable thus reducing length of stay and avoiding the possibility 
of hospital complications and surcharges on the national tariffs.  
We use Data Envelopment Analysis (DEA) to compute the potential cost savings at each 
Practice as we progressively relax the assumptions about the possibility of switching between 
types of referral and drug use, and introduce the notion of potentially improving on unit costs 
at each Practice. An implicit assumption is made in our analysis: that Practices deliver similar 
levels of quality of health care where clinical outcomes are concerned. It is noted that in the 
context of this study quality of care relates only to the service the Practice provides in terms of 
referring a patient when appropriate and/or prescribing drugs. It does not relate to the quality 
of care the patient ultimately receives in hospital and the consequent clinical outcomes.  Our 
approach to an extent captures quality of care where costs are concerned. If the Practice 
refers when it should not this will show up as cost inefficiency in our model but it will not 
capture additional discomfort to the patient undergoing potentially unnecessary tests.  If the 
Practice does not refer when it should then this can ultimately result in an emergency 
admission which again can show up as higher cost than a planned admission to hospital but 
again the potential damage to the patient through delayed treatment is not captured. In the 
case of Practice-prescribed drug treatment our model does not capture the potential ill effects 
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of unsuitable drug treatments but it does capture uneconomic drug prescription.  Thus while 
the model does capture  the quality of care in terms of its impact on costs it does not capture 
impact on the clinical condition of the patient and in that sense we need to assume that 
Practices deliver similar quality of care in terms of medical outcomes. As variables relating to 
clinical outcomes were not  available to us, we have left quality of clinical care issues to be 
addressed in future research. 
This paper is structured as follows: In Section 2 we present some previous studies on 
primary health care efficiency, analyzing with some detail those that most closely relate to the 
approach presented in this paper. In Section 3 we present the models used, and in Section 4 
the results for 75 GP units analysed. Section 5 concludes the paper.  
2. Related  Literature  
Health studies can be undertaken at several levels of analysis (e.g. patient, service 
department, hospital, primary care units, health districts, etc.). In his most recent literature 
review in this area, Hollingsworth (2008) reports that 50% of health applications concern 
hospitals and only about 10% concern primary care (in a total of 17 studies). In Amado and 
Dyson (2008) a literature review on primary health care applications is undertaken and the 
authors report about 21 studies using the DEA methodology.  
The studies on primary care have mainly looked at the efficiency of providing the health 
service, i.e. the efficiency of translating resources available (staff, materials and technology) 
into health intermediate outputs (such as consultations and treatments of various types). 
Examples of such studies include Szczepura et al. (1993), Zavras et al. (2002) or Amado and 
Santos (2009). This type of studies can be seen as addressing health care provision from a 
managerial perspective (as termed by Chilingerian and Sherman, 2004) as opposed to a clinical 
perspective, where the focus is on analyzing how a Practice utilizes the minimal quantity of 
clinical resources (such as consultations, referrals, treatments, and drugs) to achieve a 
constant quality outcome, when caring for patients with similar diagnosis complexity and 
severity. These perspectives embody two important concepts in health contexts: that of 
outputs or intermediate outputs (related to the quantity of care provided) and that of 
outcomes (related to the quality of care provided) (see Donabedian, 1980). Typically the 
transformation of inputs into intermediate outputs is seen as an efficiency assessment and the 
transformation of intermediate outputs into outcomes is seen as an effectiveness assessment. 
Amado and Dyson (2009) complement these perspectives with a third perspective of 
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assessment related to equity. For that purpose, they define in addition to inputs, intermediate 
outputs, and outcomes, also local needs. The comparison between the services provided 
(intermediate outputs) and the local needs yields a measure of relative equity across Practices.  
A number of studies, e.g. Salinas-Jimenez and Smith (1996), Luoma et al. (1996), Puig-Junoy 
and Ortún (2004), Staat (2003, 2011), Sørensen et al. (2009), and Thanassoulis et al. (2012) 
have adopted a cost perspective for the assessment of GP units, which can be seen as an 
additional perspective of analysis relative to the managerial and clinical perspectives noted 
above. All these studies have compared the costs of providing the service (like referral or 
medication costs), controlling for certain characteristics of the patients concerned such as age, 
gender, or level of deprivation. For example, Sørensen et al. (2009) used as a control variable 
the population served by the Practice divided into 22 categories reflecting age, gender, 
education and employment. These ‘output’ measures are not intermediate outputs or 
outcomes as reported above, but they work as control variables for undertaking cost 
comparisons between Practices.  
There are not many studies on primary care that focus on the analysis of a single specialty. 
Specialty or disease level analysis is more frequent in hospital studies, where the complexity 
and heterogeneity of services offered and patients treated recommends the benchmarking of 
similar hospital units (like obstetrician departments in Laudicella et al., 2010, or intensive care 
units (ICU) in Puig- Junoy, 1998 or Dervaux et al., 2009) or groups of diseases (e.g. like diabetes 
in Kristensen et al., 2010, or the DRG - Heart Failure and Shock in Dismuke and Sena, 2001). 
Some examples of studies in primary care focusing on a given specialty/disease are Linna et al. 
(2003), who analysed oral health care in Finnish health centers through a DEA method, Amado 
and Dyson (2009), who analysed diabetes in primary care in the UK using DEA, Thanassoulis et 
al. (1995) who used DEA to assess the provision of perinatal care in district health authorities 
in the UK, or Ozcan (1998) who used DEA to assess otitis media treatment by primary care 
physicians in the US. Even if these studies focus on a particular disease they still use different 
levels of analysis: physicians in Ozcan (1998), district health authorities in Thanassoulis et al. 
(1995), and health centers in Linna et al. (2003) and Amado and Dyson (2009). Given the 
differences in the assessed disease in each of the above studies, the input/output 
specifications are also different and are not indeed comparable. In some of these 
specialty/disease studies a managerial perspective of analysis was used, where inputs related 
to full time equivalent doctors and nurses dedicated to the disease (e.g. Linna et al, 2003, 
Amado and Dyson, 2009, Thanassoulis et al., 1995). The outputs used varied by disease or 
specialty. They related to the number of patients or visits to dentists in Linna et al. (2003), the 
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number of diabetics with a complete annual review, on targeted anti-hypertensive medication 
and on target statins in Amado and Dyson (2009), and to the number of birth episodes, of 
deliveries, of abortions, of special care consultants episodes, and of intensive care consultant 
episodes in Thanassoulis et al. (1995). A clinical perspective of analysis was also followed in 
Amado and Dyson (2009) where the authors used the above mentioned outputs as inputs of a 
DEA model, whose outcomes were the number of diabetics with blood pressure, blood glucose 
and blood cholesterol under control. Thanassoulis et al. (1995) were amongst the first to 
consider some outcomes in the analysis, but did that in a single model rather than through two 
separate models as done in Amado and Dyson (2009) (and advocated in Chillingerian and 
Sherman, 2004). They considered service quality variables related to number of very satisfied, 
and number of satisfied mothers with the service, and a variable relating to the quality of the 
medical outcome: survival rate of babies at risk. Ozcan (1998), on the other hand, used a set of 
inputs that relate to a clinical perspective, but on the output side of the analysis he did not use 
outcome measures, but variables that reflected the severity weight of the treated patients 
(number of low severity, medium severity and high severity patients). Inputs of the analysis 
were intermediate outputs relating to the number of visits to the primary care physician and to 
the specialist, the number of inpatients, and the number of prescriptions and laboratory 
procedures. Our analysis follows more closely the approach of Ozcan (1998) in the sense that 
we also use some proxies for controlling for the severity of patients treated at the GMG 
specialty, but on the input side we are concerned with referrals and drug prescriptions 
volumes and costs. 
3. DEA Models Used 
The aim of our study was to identify potential cost savings at 75 Practices in providing care 
for patients with medical conditions treated within the General Medicine and Geriatrics (GMG) 
clinical specialty. The savings were to be identified as in Thanassoulis et al. (2012) as we 
progressively relax the assumptions about available potential trade-offs between type of 
referral and drugs and also exploiting flexibilities in securing better unit costs for referrals and 
drugs. We used DEA for estimating the potential savings. The identification of the input-output 
variables to be used is detailed in the next section. We use generic variables in this section in 
order to present the DEA models used.  
 Consider for Practice j (j = 1, ..., n) a vector ),...,,( 21 mjjjj xxx=x  reflecting m inputs 
consumed for producing a vector of s outputs ),...,,( 21 sjjjj yyy=y . Consider also, that 
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prices of inputs are known and given for Practice j by a vector ),...,,( 21 mjjjj ppp=p .  To 
estimate savings through simply reducing input quantities we used the model in (1). This yields 
in DEA terms the “ Technical efficiency” for Practice o in the form of the optimal value θ* of θ. 
Note that the model in (1) assumes variable returns to scale (VRS) which is a realistic 
assumption in our study as will be clear when we detail the input-output variables.  
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The optimal value  θ* in (1) , indicates the degree of cost savings that Practice o can achieve 
by reducing input volumes radially, without compromising the level of outputs produced. 
To estimate potential savings taking into account not only the quantities of inputs used but 
also their unit costs we solved the classical “cost efficiency” DEA model reproduced in (2). In 
this model for Practice o we determine the levels of the input quantities xi that would minimize 
the aggregate cost C of delivering its output levels y0.  The model maintains as in (1) the 
assumption of variable returns to scale.  






≥=≥≤= ∑∑∑∑
====
0,,1,,|
1111,
ij
n
j
j
n
j
rorjj
n
j
iijj
m
i
iio
x
xyyxxxpCMin
ji
λλλλ
λ
                (2) 
The model leads to the measure of “Cost efficiency” of Practice o as the ratio between the 
minimum cost (derived from (2)) (C*) and observed cost, (C*/Co). Cost efficiency can be 
decomposed into technical and allocative efficiency. The latter is computed as: cost 
efficiency/technical efficiency. 
Allocative efficiency measures the savings that are feasible after a Practice achieves full 
technical efficiency as determined in model (1). These additional savings can result by a 
Practice aligning the mix of inputs (and not just reducing pro rata their volumes) more in line 
with observed input prices.  
Model (2) implicitly takes input prices as exogenously fixed. However, if we assume that a 
Practice can to an extent avail itself of input prices that might be more favourable for lowering 
the aggregate cost of its outputs than its current prices, then additional savings might be 
possible. To identify the potential for such savings we solved model (3).  This model leads to 
the measure of the “price efficiency” of Practice o.  In model (3), (introduced in Thanassoulis et 
al. (2012) and inspired by Tone and Tsutsui (2007)),  CiT=pixi* represent component costs, the 
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ith relating to input i, using the level xi* of input i  as derived from the cost minimizing model in  
(2).  
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Let the optimal objective function value in (3) be  C**. It is easily seen that C** ≤ C*. If C**< C* 
then model (3) has identified savings beyond those identified by model (2). These savings 
would be consequent on altering input prices and input mix simultaneously. There is no easy 
way to disentangle the effects of input price and mix alterations. Given that model (2) exhausts 
savings attainable through altering input volumes and mix to exploit observed prices at the 
Practice we will attribute any further savings identified by model (3) to input price changes 
though acknowledging that the savings could also be the result of input volume mix as well as 
input price changes. However, the volume mix changes at this stage are consequent to input 
price changes and so in a sense all savings identified by model (3) are the result of input price 
changes.  
Note that overall cost efficiency is oCC /** , the denominator being the observed cost at 
Practice o.  This ratio can be seen as the product of cost efficiency defined earlier as oCC /* , 
and “price efficiency” defined as *** / CC , since we have: *
*****
C
C
C
C
C
C
oo ×= .  
4. Identifying inputs and outputs at the GMG Specialty Level 
The analysis at the specialty level revealed some challenges in identifying inputs and 
outputs, partly because the data needed is not generally available at specialty level. Table 1 
shows the input-output variables that were ultimately identified for assessing the GMG 
specialty of Practices.  We detail here their definition and derivation.   
On the left column under ‘Inputs’ we show the modelled costs. These are broken down to 
the three main types of cost a GMG patient can incur. That is, as an inpatient at some hospital, 
as an outpatient at some hospital and through drug treatment outside hospital, though this 
may be as a follow up of a spell as an in or out patient. We use these variables in turn as 
volumes or costs of referrals depending on whether technical or cost efficiency is being 
assessed. We have used the actual rather than tariff unit cost because we want to identify any 
potential savings in actual rather than tariff expenditure. Despite the PbR tariff system, 
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contractual arrangements with provider hospitals can mean that a PCT pays in some instances 
a different amount to what the PbR tariff would dictate. 
Table 1: Input and output variables: the GMG specialty  
Inputs Outputs 
- Inpatient referrals (cost and volume) 
- Outpatient referrals (cost and volume) 
- Drug prescriptions (cost and volume) 
 
- Nature and Volume of Diagnoses driving  inpatient 
referrals (SI); 
- Nature and Volume of Diagnoses driving  outpatient 
referrals (SO); 
- Practice list population above 48 years of age 
 
 
The variables listed as Outputs in Table 1 can be seen as control variables so that Practices 
can be compared on the Inputs. Collectively the three variables are intended to reflect what 
drives the GMG specialty costs being modeled.     
 
So far as the inpatient referral volumes and costs being modeled are concerned the driver is 
clearly medical diagnoses pertaining to admissions to the GMG specialty. These were available 
to us at patient level.  We used the tariff costs of these diagnoses to construct the proxy 
variable denoted in Table 1 as (SI) aggregating to Practice level as detailed in section 4.2 below.  
The tariff costs reflect the average cost of treating the medical condition pertaining to the 
medical diagnosis.  However, no diagnoses were available to us pertaining to outpatient 
referrals to the GMG specialty nor to drug prescriptions relating to the GMG specialty. The 
remainder of this section describes how despite this lack of specialty specific data  we derived 
the proxy variables driving outpatient referrals and drug prescriptions pertaining to the GMG 
Specialty.   
4.1 Variables to reflect the need for GMG related drug prescriptions 
Drug costs and volumes were available at Practice level and not at the specialty level as 
needed. The input variable relating to drug volumes and costs is therefore a constructed 
variable, which is in turn the sum of the volumes and costs of a number of drug categories that 
were deemed to relate primarily, if not exclusively, to the GMG specialty.  
The approach we used for identifying the drug categories that were deemed most related 
to the specialty under assessment was to regress each drug cost (we had 59 drug categories 
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and respective costs) on three variables: Practice list population, inpatient volumes for the 
GMG specialty and outpatient volumes for the GMG specialty. If the cost of a certain category 
of drug was explained mainly by list size and not by the volume of inpatient and outpatient 
referrals within the GMG specialty, then this category of drug was deemed not to be related 
much with this specialty; on the other hand, if the cost of a certain category of drug was 
explained mainly by the specialty inpatient and outpatient referrals and not by list size, and the 
model provides a good fit (R-squared above 70%), then that category of drug was deemed to 
be related primarily with the GMG specialty. As a result of this analysis we identified 21 out of 
the 59 drug categories as relating primarily to the GMG specialty. These ranged from Lipid 
regulating drugs to drugs used in diabetes, antidepressant drugs and so on. The list of drugs 
was discussed with clinical doctors and health care managers in a specially convened workshop 
and was deemed a good proxy for the drugs that are mostly prescribed to patients diagnosed 
with conditions covered by the GMG specialty. 
The volumes and costs of the GMG related categories of drugs identified were summed in 
turn to yield the variable for the volume and cost of drugs used as an input in Table 1.   
4.2 Diagnoses driving referrals and drug prescriptions of the GMG specialty 
One key way to capture the medical condition of patients, as it pertains to the need for 
referrals and drugs of the GMG specialty, is with reference to diagnoses mapped to the GMG 
specialty. In the year of analysis (2007/8) ICD codes were available only for those patients who 
had had at least one episode as an inpatient. The primary diagnosis (ICD) of each inpatient 
leads to a Healthcare Resource Group (HRG) tariff. We identified 52 HRGs that related very 
directly with the GMG specialty with the help of a Physician. These varied from the most 
frequent HRG like F06 - Diagnostic Procedures, Oesophagus and Stomach, or E36 - Chest Pain 
<70 with or without out complication to some less frequent HRGs like A20 - Transient 
Ischaemic Attack >69 or with complications. These diagnoses have been suitably aggregated to 
construct the first two proxy variables appearing under ‘outputs’ in Table 1. The proxy variable 
termed SI (Severity of health conditions of Inpatients) is derived from the GMG specialty 
inpatient diagnoses. It is the aggregate quantity computed as: 
 (4)
 
In (4) we aggregate, for each Practice, the volume of patients within each of the HRGs 
considered relevant for the GMG specialty. The 52 HRGs are weighted by the tariff for that 
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HRG category, which reflects the cost for treating the diagnosis concerned as set by the 
Department of Health. The tariff reflects among other things the severity of the disease 
concerned, any comorbidities, age and gender of the patient. HRG tariffs are different 
depending on whether a patient is an elective or non-elective (emergency) admission. The 
above computation of the proxy variable reflects the fact that on average 15% of inpatient 
admissions to the GMG specialty were elective and the rest non-elective. For the first 52 HRGs, 
those accounting for most inpatients in the GMG  specialty by volume, we have used the actual 
tariff. The remaining HRGs were grouped into HRG category 53 and its tariff was taken as the 
average tariff of all HRGs included in this category labelled as ‘other’. 
The foregoing proxy variable reflects primarily the volume and cost of medical conditions 
within the list population driving inpatient referrals and indirectly the use of drugs. A second 
proxy variable was sought (SO – Severity of health conditions of Outpatients), which would 
more directly relate to medical conditions driving outpatient referrals to the GMG specialty 
and drug use within that specialty. Here we faced the problem that for outpatients there is no 
diagnosis or HRG associated with each outpatient referral. We proceeded nevertheless on the 
assumption that inpatient referrals, whether or not to the GMG specialty, do reflect medical 
conditions in the aggregate across the list population of a Practice and some of them, 
depending on inpatient diagnosis, could have had outpatient referrals to the GMG specialty. In 
addition, list patients without any inpatient referral in the year under consideration could have 
also had outpatient referrals to the GMG specialty. A preliminary analysis of outpatient 
referrals found that 53% of outpatient referrals to the GMG specialty had not had an inpatient 
referral of any kind in the year of analysis while the rest (47%) of outpatient referrals to this 
specialty did have at least one inpatient referral that year, but not necessarily to the GMG 
specialty.    
To identify the inpatient health conditions that most closely relate to outpatient referrals in 
the GMG specialty we proceeded as follows. Using patient level data we examined all 
categories of inpatient diagnosis, and for each category we aggregated the number and cost of 
outpatient referrals to the GMG specialty. In this way we could identify two-digit ICD 
categories which tended to also generate volume and cost of outpatient referrals to the GMG 
specialty. The following percentages, were then used to select ICDs that generate referrals to 
the GMG specialty: 
- PC1: Percentage of all outpatient referrals to the GMG specialty accounted for by 
outpatients who had a given ICD; 
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- PC2: Percentage of total cost of outpatient referrals to the GMG specialty accounted 
for by outpatients who had a given ICD.  
These related percentages capture the ICDs that drive outpatient volumes and costs of the 
GMG specialty from those persons in a Practice’s list who also have had some type of inpatient 
episode in the year of analysis. The values of PC1 range from 0% to 6.55% and the values of 
PC2 range from 0% to 5.94%. The highest percentages pertain to ICD K5 - non-infective 
enteritis and colitis; other diseases of intestines, meaning that about 6.6% of outpatient 
referrals to the GMG specialty pertained to patients that have also been referred as inpatients 
under the ICD K5. We selected those ICDs that showed PC1 or PC2 above 1%. 33 ICD categories 
satisfied these criteria and their costs were summed to construct the second proxy variable 
(SO) appearing under outputs in Table 1.  
The two proxy variables under outputs just described do capture the impact on referrals 
and indirectly on drugs for the GMG specialty but only in respect of patients who had had 
some inpatient referral. Clearly the outpatient referrals and drugs of the GMG specialty are 
also driven by list patients who did not have any inpatient referral in the year under 
consideration. In order to capture such additional demand for the GMG specialty outpatient 
referrals and drugs we regressed each one of the three variables under Inputs in Table 1, both 
in cost and volume format, on the two proxy output variables and additional variables 
reflecting the list size of the practice by age and gender as defined in Table 2. These groupings 
are as used in Thanassoulis et al. (2012) and are based on medical consensus in that all those 
within a given age/gender group who have a given socio economic profile, (also allowed for as 
will be noted below), will represent on average similar health needs.   
 
The best regressions identified in terms of explanatory power were those that involved, in 
addition to the two proxy output variables constructed above, the number of list patients a 
practice had that were aged above 48 years (constructed by adding the number of people in 
the two last groups in Table 2).  This constitutes the third proxy variable listed under Outputs 
in Table 1.   
Table 2:Age/gender groups considered 
Age/gender group Average % of Practice list patients 
age < 3 3.09% 
age >=  3 and age < 18 17.58% 
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age >= 18 and age < 35 and sex = Male 10.23% 
age >= 18 and age < 35 and sex = Female 9.84% 
age >=  35 and age < 48 and sex = Male 10.48% 
age >=  35 and age < 48 and sex = Female 9.92% 
age >= 48 and age < 70 27.11% 
age >= 70 11.74% 
 
Regressions were also run in which each age/gender band in Table 2 was divided into 
patients above and below the 80th percentile on “index of Multiple Deprivations” (see 
Thanassoulis et al., 2012). However, the additional variables of ‘deprivation’ did not prove 
significant in this context, partially because patients on each age band, above and below the 
80th national percentile of deprivation, was considered at the Practice level rather than at the 
Specialty level. 
Table 3 shows the explanatory power the three proxy output variables have for each one of 
the three inputs variables in turn when regressed in volume format (VI, VO and VD) or cost 
format (CI, CO and CD). I, O and D stand respectively for in, and out patient referrals and D for 
drugs, all relating to the GMG specialty.  
Table 3: Results from regressing each input variable on the three proxy output variables of Table 1. 
 CI VI CO VO CD VD 
Proxy for inpatient 
referrals (SI)  
462(.000) .0481(.000) -55.5(.000) -.415(.000) -146(.214) 9.762(.613) 
Proxy for outpatient 
referrals (SO) 
571(.000) -.025(.316) 251(.000) 2.14(.000) 1387(.000) 93.16(.016) 
List Age 48+ 9.15(.409) -.004(.170) 15.29(.000) .12(.000) 189.7(.000) 18.75(.000) 
R2 97.0% 99.4% 93.5% 93.9% 92.9% 83.7% 
St error  
(% average) 
48094.74 
(9.85%) 
13.80 
(4.7%) 
11594.05 
(14.99%) 
96.33 
(14.37%) 
1.27009E5 
(15.71%) 
20911.23 
(23.8%) 
 
Values in bold correspond to the coefficients that are statistically significant in each 
regression. As can be seen the 3 proxy output variables explain well over 90% of the volume or 
cost of each input variable, the exception being the volume of the GMG specialty prescriptions 
which are explained only at about the 84% level. These levels of explanatory power are 
considered satisfactory and we proceeded with the analysis using the ‘input’ - ‘output’ set in 
Table 1, with the proxy variables constructed as outlined above.  
One additional issue was that of returns to scale that should be maintained in setting up the 
DEA models.  We opted for the least restrictive assumption, that of variable returns to scale. 
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That is, given the variables in Table 1 we cannot assume that a proportional rise or fall of 
referrals or drugs will match precisely a proportional rise or fall in the levels of the output 
variables. 
Descriptive statistics for the 75 Practices, on the variables in Table 1 are shown in Table 4. 
These statistics show that there is a considerable variation across Practices as for all variables 
the coefficient of variation is above 1.6. This heterogeneity in the size of the list of Practices 
was another argument for the use of a VRS technology. 
Table 4: Descriptive statistics of the variables 
 Average Max Min Stdev Coef Var 
VI 293.33 603 51 169.12 1.734 
CI 488,167.76 1,128,117.69 67,775.21 270,754.98 1.803 
VO 670.31 1,699 150 382.36 1.753 
CO 77,364.27 205,749.9 18,131.61 44,511.27 1.738 
VD 87,879.28 226,036 21,36 50,732.69 1.732 
CD 808,643.67 2,180,670.19 189,716.41 467,433.84 1.730 
SI 641,642.34 1,348,702.747 116,229.92 370,774.44 1.731 
SO 268,190.95 622,385.64 30,903.9 154,879.03 1.732 
List 48+ 2,657.61 6,281 496 1,575.76 1.687 
 
5. Results 
Our analysis relates to data for the financial year 1/4/2007 to 31/3/2008. In terms of 
contributions to overall costs, drugs represent the highest share at 58.85% of the total costs. 
Inpatient referral costs account for 35.52% of total costs and the balance of 5.63% is 
accounted for by outpatient referrals. It should be noted that the contribution of drug costs to 
overall costs in the GMG specialty may be exaggerated here in that the drugs we have 
identified as relating in the main to the GMG specialty may also include patient prescriptions 
which are not related to the GMG specialty. The converse is of course also possible that the 
drugs we have excluded may include prescriptions for patients who might otherwise have had 
or indeed did have the GMG specialty referrals. This ambiguity cannot be resolved without 
attribution of drugs to specialties at the prescription stage, data not available to us. The 
percentage of 58.85% of total costs being accounted for by drugs is not, however, too far from 
the 51% of costs that drugs account for when costs are seen at Practice rather than specialty 
level.  
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5.1. Estimating the scope for savings 
We estimate the overall savings progressively in three phases, gradually relaxing the 
assumptions about the alternatives open to a GP for managing clinical conditions of patients 
presenting with conditions relating to the GMG specialty. The three phases in terms of the 
assumptions underpinning them are respectively as follows: 
There is no scope for switching between inpatient, outpatient referrals and drugs at the GMG 
specialty level; 
There is scope for switching between inpatient, outpatient referrals and drugs at the GMG 
specialty level but unit costs are fixed; 
There is scope for switching between inpatient, outpatient referrals and drugs at the GMG 
specialty level and unit costs can be varied. 
Phase 1: Assuming there is no scope for switching between inpatient, outpatient referrals 
and drugs pertaining to the GMG specialty. 
Under this assumption the variables in Table 1 are used in volume terms and costs of 
referrals and drugs are not taken into account. The assumption is that the only option open to 
the Practice for savings is to reduce the volumes of referrals and drugs to levels more 
compatible with those of benchmark Practices facing a similar mix of health conditions of 
inpatients and outpatients and number of list patients aged over 48 years. The generic DEA 
model compatible with this assumption is Model (1). Under the foregoing assumption we 
identify aggregate cost savings across the 75 Practices on the order of 3% of observed total 
expenditure.   
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Figure 1: Potential savings as percentage of aggregate actual expenditure 
As can be seen in Figure 1 there is a substantial difference between Practices on their 
potential for savings. More than half the Practices have no scope for reducing the volumes of 
referrals and prescriptions but some 12 Practices have potential to save in excess of 8% of 
their costs by simply reducing the volume of referrals and drugs. Overall, however, we find the 
potential for reducing referrals to the GMG specialty and prescriptions in pure volume terms is 
relatively low. 
Phase 2:  Assuming there is scope for switching between inpatient, outpatient referrals and 
drugs pertaining to the GMG specialty maintaining unit costs 
Under this assumption the DEA model is configured so that we estimate the minimum 
aggregate referrals and drug costs a Practice could have incurred in relation to the GMG 
specialty, controlling for the diagnoses and list population above 48 years of age that drive 
those costs. Thus we relax the Phase 1 assumption that these drivers pretty well determine the 
mix of treatment pathways that are needed in the GMG specialty at the Practice. Rather, 
through the model we enquire whether a given Practice could have adopted some 
combination of referrals and drugs modelled on benchmarks, which would minimise its 
aggregate cost of referrals and drugs pertaining to the GMG specialty, given the health profile 
of its patients and the unit costs (or prices) it faces.  
The model solved in this phase is the classical cost efficiency DEA model (2). We identify 
during this phase considerable scope for savings (see Table 5). Clearly most cost savings can be 
obtained from switching between inpatient, outpatient and drug pathways than from pro rata 
changes of their volumes.   
Table 5:  Scope for savings by switching treatment pathways at observed unit costs of referrals and 
prescriptions  
 % of actual GMG specialty 
referrals and drugs expenditure 
Total phases 1 and 2 10.97%  
Phase 1 2.59% 
Phase 2 8.38% 
 
Table 5 clearly shows the enhanced scope for savings that opens up when we allow for 
switching between treatment pathways rather than maintaining the mix of referral and drug 
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pathways and simply lowering their volumes. Figure 2 shows the range in the potential for 
savings in the GMG specialty in aggregate through volume decreases (Phase 1) and referral 
and drugs volume mix adjustments (Phase 2).  
 
Figure 2: Scope for savings as percentage of actual aggregate referrals and prescriptions expenditure 
The scope for savings, as we might expect, increases when we allow for adjustments to the 
mix of referrals and drugs. The median practice can now save about 10% of its aggregate cost, 
and 20% of the practices can save above 20% of their aggregate cost.  
Table 6 summarises the adjustments to the volume of inpatient (VI) and outpatient (VO) 
referrals and drug volumes (VD) that Practices need to make to effect the savings identified in 
Phase 2. The columns show the ratio of Target volumes (named TVI, TVO, TVD) to observed 
volumes, the former having been identified via model (2). For example, 30 practices need to 
raise their inpatient referrals, 18 to keep them as they are, and 27 to lower them. The average 
change is a rise in inpatient referrals of 1.4%, and a reduction in outpatient referrals to 97.4% 
of observed levels. The main overall change the table suggests is a drop of over 18% in 
prescriptions, though it should be noted that this does not take into account the differences in 
volumes of drug prescriptions by Practice. That is, certain Practices may prescribe a higher 
number of doses per prescription than others for certain drugs. Information at that level of 
detail was not available to us.  It is noteworthy that in Table 6 for no Practice do we find that it 
would be cost-effective to increase the volume of drug prescriptions.  
Table 6: Number of Practices needing to change referral and drug volumes to minimise costs at 
observed unit costs 
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 TVI/VI TVO/VO TVD/VD 
# >1 30 23 0 
# =1 18 18 18 
# <1 27 34 57 
Average 1.014 0.974 0.817 
Maximum 1.360 1.346 1.000 
Minimum 0.873 0.481 0.486 
 
Phase 3:  Estimating the scope for savings when we permit adjustments to volumes and mix 
of referrals and drugs, and to their unit costs 
This phase represents the ultimate relaxation of assumptions. We assume that for 
managing medical conditions of the GMG patients not only can Practices opt for a mix of 
referrals and prescriptions by volume that best suit their unit costs, but that those unit costs 
themselves may be capable of adjustment. The model solved at this stage was model (3). This 
model applies the traditional DEA assumption that a virtual Practice can be constructed as an 
average of those observed, with the only difference being that the average is over the optimal 
(for observed prices) inpatient, outpatient and drug cost components as defined in that model 
rather than the volumes of those variables, used traditionally. This in turn implies that 
controlling for disease weight as proxied in the outputs of the model a Practice should in 
principle be capable of attaining the optimal mix of outputs and cost components of other 
benchmark practices, and the unit costs implicit in those cost components.  
Under these relaxed assumptions we identify additional cost savings in the GMG specialty 
across the 75 practices amounting to nearly 7% of observed expenditure. See Table 7. 
Table 7: Scope for savings by switching treatment pathways and adjusting unit costs of referrals and 
prescriptions in the GMG Specialty 
 % of actual GMG specialty 
referrals and drugs expenditure 
Total across 3 phases  17.39% 
Phases 1 and 2 10.97% 
Phase 3 6.42% 
 
Figure 3 shows the range of the potential for savings in the GMG specialty at Practice level. 
The scope for savings, as we might expect, increases when we allow for adjustments not only 
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to the mix of referrals and drugs but to joint adjustments of unit costs and volumes. The 
median practice can now save about 18% of its aggregate drugs and referrals costs compared 
to 10% when only the level and mix of volumes could be adjusted.   
 
Figure 3: Scope for savings as percent of actual aggregate referrals and prescriptions expenditure - unit 
cost adjustments permitted 
In Figure 3 we can see that Practices show different profiles for attaining cost savings. For 
example Practice G3 is only inefficient in allocative terms, meaning that the only way to effect 
the savings identified for this Practice is by changing its mix of inputs (referrals and drugs). On 
the other hand, Practice G55 is only inefficient in terms of unit costs, meaning that the only 
way to achieve the cost savings for this Practice is through a change in the unit costs it ‘pays’. 
Below in Figure 4 we can see two radar graphs that compare these two units with some of 
their main benchmarks as identified by the respective DEA model. In these graphs the input-
output values for the inefficient practice (G3 and G55 respectively) have been normalized to 1. 
  
Figure 4: Practices G3 and G55 Compared with some benchmarks 
Practice G3 is only inefficient in allocative terms. That is, the volumes of referrals and drugs 
cannot all reduce pro rata, but their mix (ratio to each other) can be altered to minimize their 
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aggregate cost. Observed average prices for G3 are 1,835 for inpatient referrals, 104.4 for 
outpatient referrals, and 8.1 for drugs prescriptions, in pounds sterling. In general the 
minimization of costs is mainly achievable through changing inpatient referrals, as across all 
Practices unit costs are much higher for these referrals in comparison to outpatient referrals.  
In the left panel of Figure 4 we can see that practice G4 (the cost benchmark of G3) shows 
higher outputs (about 1.3 times more severe health conditions of patients than G3) and 
simultaneously shows a lower volume of drug prescriptions, a volume of outpatient referrals 
that is about 1.6 times of that of G3, and a volume of inpatient referrals that is only about 1.2 
times of that of G3. Therefore Practice G4 shows a balance of referrals that favours the less 
expensive referrals in relation to the most expensive ones. Therefore model (2) identifies that 
the volume of outpatient referrals of G3 should increase by 15%, and that of inpatient referrals 
and of drug prescriptions of G3 should decrease by 3.5% and 36%, respectively. Note that the 
price of prescriptions does not play a major role in determining drug prescription targets, as 
drug prescriptions unit costs are very low, and indeed minimization of this component of cost 
is mainly achieved through volume changes (as will be clearer later). Therefore actions at 
Practice G3 to increase outpatient referrals and decrease drug prescriptions would reduce 
overall costs. 
Practice G55 is only inefficient in input price terms (unit costs of referrals and drugs). From 
model (3) Practices G54 and G49 are two of its main benchmarks in terms of input prices. As 
we can see on the right panel of Figure 4 the two benchmark practices show similar unit costs 
to G55 on outpatient referrals (PO), but much lower unit costs of drugs (PD) and inpatient 
referrals (PI). The lower prices cannot be explained by higher volumes at the benchmarks, 
since both benchmark practices show lower volumes of inpatient referrals than Practice G55. 
Note that the price benchmark Practices are not necessarily efficient on the other dimensions, 
so the differing volumes may reveal inefficiency of these price benchmarks on the other 
dimensions. 
5.2. Overview of the changes Practices need to make to realize the 
savings identified 
It is instructive to look at the detail of changes in referrals and prescriptions that each 
practice would need to make in order to achieve the cost savings identified in the previous 
section. We look at these changes under two alternative assumptions: that unit costs of 
referrals and prescriptions cannot be changed and that they can be changed. 
Case 1: Changes needed when unit costs of referrals and prescriptions remain as observed  
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When we consider the potential for Practices to minimize aggregate expenditure by 
exploiting the potential to change the volume and mix of treatment pathways then Figure 5 
summarises the changes needed across the 75 Practices assessed. TVI, TVO and TVD are the 
target volumes of inpatient, outpatient referrals and prescriptions respectively to minimise 
total costs under current unit prices. In Figure 5 TVI/VI, TVO/VO and TVD/VD are the target 
volumes expressed as fractions of the actual levels of inpatient and outpatient referrals and 
prescriptions, respectively.  
 
Figure 5: Referral and prescription mix changes to minimise aggregate costs under existing unit costs 
As can be seen in Figure 5 the main change needed is the reduction in the volume of 
prescriptions down to about 81% of current volumes. Reductions in outpatient referrals 
needed are also considerable down to about 97% of current levels. The volume of inpatient 
referrals can increase slightly by about 1% if these savings in volumes of outpatients and drugs 
are to be attained.  
Case 2:  Changes needed to achieve the estimated savings when unit costs of referrals and 
prescriptions need not remain as observed  
As we saw earlier, when we assume that through a judicious choice of health providers and 
treatment pathways a practice may be able to change both the mix of referrals and 
prescriptions and their unit costs, the total sum of savings attainable in the GMG specialty is of 
the order of 18% of total expenditure on referrals and prescriptions across all 75 practices.   
Figure 7 summarises the mix of changes needed to realize the savings identified both in 
terms of volumes and in terms of unit costs. The left panel in Figure 7 identifies the scope for 
savings in volume terms and is therefore equivalent to the graph in Figure 5.  
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Figure 6: Referral and prescription mix and unit cost changes to minimise aggregate costs 
The changes to unit costs needed are summarised in the right panel of Figure 6. Looking at 
that panel the ratio PIT/PI is that of the target unit cost for inpatient referrals to its actual 
level. Mean values of PIT and PI are used. The remaining two ratios in the right panel of Figure 
6 are defined in a similar manner. The panel suggests that there is scope for substantial 
reductions in inpatient unit costs in the GMG specialty of the order of 10% on average. 
Similarly, there is scope for about 7% reduction in unit cost of drugs while outpatient costs on 
the other hand can rise by about 1.3% on average to compensate for the inpatient and 
prescription unit cost reductions.   
We conclude this section by summarising in Table 8 the components of cost savings 
attributable to each type of volume and/or unit cost adjustment. 
Table 8: Potential saving components by type of volume or unit cost adjustment 
Inpatient volume adjustment -1.05 
Outpatient volume adjustment 0.49 
Drugs Volume adjustments 63.65 
 Inpatient unit cost adjustments 17.80 
 Outpatient unit cost adjustments 0.22 
Drugs unit cost adjustments 18.89 
 Total scope for savings 100 
 
Clearly the bulk of cost savings can be achieved through reducing the volume of drug 
prescriptions. Two further substantial components of savings of 17%-19% of total potential 
savings are possible through reducing the unit cost of inpatient referrals and drugs. The 
remaining components of cost savings can be considered residual.  
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6. Conclusion.  
In this paper we have investigated the scope for health care cost savings at 75 GP Practices 
in relation to patients presenting with conditions that lead to treatment in the GMG specialty. 
The analysis followed that in Thanassoulis et al. (2012) where overall expenditure on health 
care across all medical specialties was investigated in aggregate. 
The analysis at the specialty level reported here was undertaken, in order to control more 
accurately for the medical conditions of those receiving medical care and thereby incurring the 
costs being modelled. An additional benefit of an analysis at Specialty level is that we gain 
better insight into the cost-efficient patient management processes as we identify such 
processes at specialty level thus avoiding overlooking potential efficiencies through averaging 
across efficient and inefficient component costs of a Practice.   
Two of the key contributions of this paper, apart from the identification of cost savings 
possibilities, are both the process of identifying input-output variables for assessments at 
specialty level and the variables themselves.  The process of identifying input-output variables 
is important because medical data at patient level are strictly confidential and so the analysis 
needs to identify medical conditions to control for, yet without straightforward access to the 
diagnoses of those conditions. We exploited the fact that for those patients that had had in the 
time period under considerations (2007/8) at least one inpatient appointment we had at 
anonymised patient level the diagnosis. However, this information was not available for those 
that had an outpatient appointment. Using data from the inpatient record and combining it 
with more general anonymised patient level data on age, gender and deprivation level of 
geographical location we identified proxy variables that explained on the order of 90% of the 
variation across Practices of volumes and costs of inpatient and outpatient referrals and over 
80% of the variation in volume and costs of drugs used.  These variables enabled health care 
costs to be set against a good representation of the disease weight driving those costs. 
 
Our analysis suggests that for the 75 Practices analysed the largest percentage of savings at 
the GMG specialty comes from changes in the mix of referrals and drug prescriptions. In 
particular, the largest components of potential savings are available through control of the use 
of drugs. The single largest component, accounting for some 63.65% of total potential savings, 
relates to a potential reduction in the volume of drug prescriptions. The second largest 
component, accounting for just under 19% of total potential savings is due to a reduction in 
the unit cost of prescriptions. Finally considerable savings of the order of 17% are available 
through better monitoring of inpatient unit costs. There is, on the face of it, the counter-
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intuitive finding the foregoing reductions appear to be contingent on a marginal rise of 
inpatient referrals.  This  suggests that in  some cases spells of inpatient episodes can reduce 
perhaps long term drug use. This finding can be further investigated by analyzing longitudinal 
data at patient level. Savings from outpatient referrals in terms of volume or unit costs are 
marginal, suggesting that the biggest sources of inefficiency are related to inpatient unit costs 
and above all volume of drug prescriptions. 
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